Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species
- PMID: 8968960
- DOI: 10.1007/BF01886751
Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species
Abstract
Botulism due to food poisoning is caused mainly by protein toxins, botulinum neurotoxins (BoNTs), produced by Clostridium botluinum in seven known immunological serotypes. These are the most potent toxins and poisons known. BoNT effects blockade of neuromuscular transmission by preventing neurotransmitter release. Human botulism is most frequently caused by types A, B, and E. Recent studies have shown that immunization with a 43-kDa C-terminal fragment (Hc, residues 860-1296) of BoNT/A affords excellent protection against BoNT/A poisoning. We raised antibodies (Abs) against BoNT/A in horse, and against pentavalent toxoid (BoNTs A, B, C, D, E) in human volunteers and outbred mice. Thirty-one 19-residue peptides that started at residue 855, overlapped consecutively by 5 residues, and encompassed the entire length of the Hc of BoNT/A were synthesized and used for mapping the Ab-binding regions recognized by the anti-BoNT/A antisera. Horse Abs against BoBT/A were bound by peptides 855-873, 939-957, 1079-1097/1093-1111 overlap, 1191-1209/1205-1223 overlap, 1261-1279 and 1275-1296. In addition, peptides 883-901, 911-929, 995-1013, 1023-1041/1037-1055 overlap, 1121-1139, and 1149-1167 gave low, but significant and reproducible, binding. With human antisera, high amounts of Abs were bound by peptides 869-887, 925-943, 981-999, 995-1013, 1051-1069, and 1177-1195. In addition, lower amounts of Abs were bound by peptides 911-929, 939-957, 967-985, and the overlaps 1121-1139/1135-1153 and 1247-1265/1261-1279/1275-1296. With outbred mouse antisera, high amounts of Abs were bound by peptides 869-887, 1051-1069, and 1177-1195, while peptides 939-957, 995-1013, 1093-1111, and 1275-1296 bound lower amounts of Abs. The results indicate that horse antiserum against BoNT/A or human and mouse (outbred) antisera against the toxoid recognized similar regions on BoNT/A, but exhibited some boundary frame shifts and differences in immunodominance of these regions among the antisera. Selected synthetic epitopes will be used as immunogens to stimulate active or passive (by Ab transfer) immunity against toxin poisoning.
Similar articles
-
Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.Immunobiology. 2012 Jan;217(1):17-27. doi: 10.1016/j.imbio.2011.08.009. Epub 2011 Aug 30. Immunobiology. 2012. PMID: 21962573
-
Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A.Protein J. 2004 Jan;23(1):39-52. doi: 10.1023/b:jopc.0000016257.91979.06. Protein J. 2004. PMID: 15115181
-
Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains.Immunobiology. 2012 Jan;217(1):1-7. doi: 10.1016/j.imbio.2011.09.001. Epub 2011 Sep 16. Immunobiology. 2012. PMID: 22015045
-
Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins.Crit Rev Immunol. 1999;19(3):219-60. Crit Rev Immunol. 1999. PMID: 10422600 Review.
-
Molecular bases of protective immune responses against botulinum neurotoxin A--how antitoxin antibodies block its action.Crit Rev Immunol. 2007;27(4):319-41. doi: 10.1615/critrevimmunol.v27.i4.30. Crit Rev Immunol. 2007. PMID: 18197812 Review.
Cited by
-
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes.Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11311-6. doi: 10.1073/pnas.0804851105. Epub 2008 Aug 4. Proc Natl Acad Sci U S A. 2008. PMID: 18678888 Free PMC article.
-
Mucosal vaccine development for botulinum intoxication.Expert Rev Vaccines. 2007 Feb;6(1):35-45. doi: 10.1586/14760584.6.1.35. Expert Rev Vaccines. 2007. PMID: 17280477 Free PMC article. Review.
-
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11782-7. doi: 10.1073/pnas.1209292109. Epub 2012 Jul 2. Proc Natl Acad Sci U S A. 2012. PMID: 22753489 Free PMC article.
-
Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum.Expert Rev Vaccines. 2008 Feb;7(1):55-74. doi: 10.1586/14760584.7.1.55. Expert Rev Vaccines. 2008. PMID: 18251694 Free PMC article. Review.
-
Isolation and characterization of Hc-targeting chimeric heavy chain antibodies neutralizing botulinum neurotoxin type B.Front Immunol. 2024 Apr 30;15:1380694. doi: 10.3389/fimmu.2024.1380694. eCollection 2024. Front Immunol. 2024. PMID: 38779676 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources